Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,178,633
  • Shares Outstanding, K 329,011
  • Annual Sales, $ 135,070 K
  • Annual Income, $ -384,730 K
  • 60-Month Beta N/A
  • Price/Sales 38.41
  • Price/Cash Flow N/A
  • Price/Book 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.50
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.28 +1.44%
on 06/17/19
23.60 -34.32%
on 05/20/19
-7.58 (-32.84%)
since 05/17/19
3-Month
15.28 +1.44%
on 06/17/19
29.79 -47.97%
on 04/08/19
-4.85 (-23.83%)
since 03/19/19

Most Recent Stories

More News
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 15.50 (-1.52%)
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 15.50 (-1.52%)
Moderna: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Moderna Inc. (MRNA) on Thursday reported a loss of $132.7 million in its first quarter.

MRNA : 15.50 (-1.52%)
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains

--Results are from Moderna's first human studies of mRNA vaccines; demonstrates a new technological approach to flu vaccine development and production

MRNA : 15.50 (-1.52%)
Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates

--Immuno-Oncology: Two personalized cancer vaccine (PCV) abstracts to be presented at the 2019 ASCO Annual Meeting

MRK : 85.36 (+1.03%)
MRNA : 15.50 (-1.52%)
Why Earnings Season Could Be Great for Moderna (MRNA)

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MRNA : 15.50 (-1.52%)
Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 15.50 (-1.52%)
Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 15.50 (-1.52%)
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today...

MRNA : 15.50 (-1.52%)
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

ABUS : 1.72 (-3.37%)
DRNA : 15.39 (-3.21%)
ARWR : 27.51 (-1.36%)
ALNY : 71.97 (-1.44%)
REGN : 310.83 (+1.37%)
MRNA : 15.50 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MRNA with:

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

2nd Resistance Point 16.45
1st Resistance Point 16.09
Last Price 15.50
1st Support Level 15.48
2nd Support Level 15.22

See More

52-Week High 29.79
Fibonacci 61.8% 23.39
Fibonacci 50% 21.41
Fibonacci 38.2% 19.43
Last Price 15.50
52-Week Low 13.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar